Featurely

Featurely targets the decisions that cannot be quietly reversed: a drug launch price, a new vehicle trim, a financial product change. Instead of relying on a handful of hand-built scenarios, it constructs a simulated version of the market from aggregate data and mirrors the people who actually decide — prescribers, payers, patients, buyers — as synthetic stakeholders in the right proportions. Teams then run each response option against every scenario worth testing, many times over, and see which option wins where.

A distinguishing feature is the causal explanation layer. Every simulated shift is traced back to a named mechanism such as switching cost, price anchoring or outcomes beating price, so the output is inspectable reasoning rather than an opaque score. The vendor publishes its prediction record — thousands of blind predictions, most directionally correct, with misses included — and offers security documentation including SOC 2 Type I attestation, a DPA and US/EU data residency.

Engagements start with a scoping call and produce a first readout in about two weeks. The company says it works with Fortune 500 firms in pharma, financial services and automotive, whose names and data stay private. It is best suited to strategy, pricing and launch teams in regulated industries rather than to casual market research.